Back

Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Debora Da Silva Correia

Hospital Santa Cruz, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy
Doctor G. Bonacchi (Florence, IT)
Abstract Slides
Presentation thumbnail
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides
Presentation thumbnail
Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort
Doctor D. Jensen (Zurich, CH)
Abstract Slides
Presentation thumbnail
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
Doctor S. Hoss (Petah Tikva, IL)
Abstract Slides
Presentation thumbnail
Impact of mavacamten on left atrial remodeling in obstructive hypertrophic cardiomyopathy: data from 3 portuguese centers
Doctor I. Miranda (Amadora, PT)
Abstract Slides

Access the full session

Session thumbnail
Cardiac myosin inhibition in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
31 August 2019
thumbnail
Congress Presentation
Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort
29 August 2022
thumbnail
Congress Presentation
Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.
22 May 2023
thumbnail
Congress Presentation
The effect of mavacamten on electrical parameters in cardiac implantable electronic devices
13 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources